Delivery Order SPE2DB20D2014-SPE2DB25FC78S
- Not listed
- The Defense Logistics Agency awarded a $5,590.59 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract is not set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be executed from the contractor's location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,570.63 on July 14, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $11,893.95 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Orencia 125 mg/ml syringes. This non-set-aside competitive award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Orencia 125 mg/mL syringes valued at $9,779.31. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order is issued under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,890.11 on June 16, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed-price delivery order, which is due for completion on June 17, 2025, was competitively awarded without set-aside designation to support the Medical Supply Chain, a division of the Defense Logistics Agency under the Department of Defense. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 7, 2025, for the supply of Orencia 125 mg/ml syringes valued at $8,772.35 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026. The contract carries no set-aside designation and was...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Orencia 125 mg/ml syringes, valued at $15,917.19 with firm fixed pricing. This competitive award, which carries no set-aside designation, is classified as a delivery order under a larger contract vehicle and is scheduled for completion by August 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order...
- The Defense Logistics Agency awarded a delivery order valued at $3,675.77 to AmerisourceBergen Drug Corp for Orencia 125 mg/ml syringes. This contract, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a firm fixed-price procurement with no set-aside designation. The award was made competitively and reflects AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is the company's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $18,423.65 by the Defense Logistics Agency on September 8, 2025, for the supply of Orencia ClickJect 125 mg/mL. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $49,728.04 to AmerisourceBergen Drug Corp for the supply of Orencia 125 mg/mL syringes. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of May 19, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC78SDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Orencia 125 mg/mL syringes, valued at $3,701.46. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal vendor for military and veteran healthcare systems. The company's substantial IDC with DLA enables it to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide, including support to the Defense Health Agency and U.S. Coast Guard. Orencia (abatacept) is a biologic immunosuppressant commonly used in the treatment of rheumatoid arthritis and other autoimmune conditions, reflecting the breadth of specialty medications within the company's federal contract portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/19/25 |